Ypsomed expands to more countries
Ypsomed invests into new subsidiaries to allow even more people with diabetes to benefit from the advantages of insulin…
Ypsomed invests into new subsidiaries to allow even more people with diabetes to benefit from the advantages of insulin…
In the first half-year of the current business year 2016/17, the Ypsomed Group generated consolidated net sales of CHF 1…
Im ersten Semester 2016/17 erzielte die Ypsomed Gruppe einen Gesamtumsatz von CHF 185.4 Mio., CHF 27.6 Mio. mehr im Verg…
To deliver innovative care solutions, that improve the lives of people with diabetes, is the focus of the collaboration…
Innovative Therapielösungen anzubieten, die das Leben von Menschen mit Diabetes verbessern, steht im Fokus der Kooperati…
From March 2016 the Ypsomed Group will be gradually introducing the tubing free insulin patch pump mylife™ OmniPod® for…
Ab März 2016 vertreibt die Ypsomed Gruppe die schlauchlose Insulin Patch-Pumpe mylife™ OmniPod® mit bestehenden Gruppeng…
Ypsomed Group and the Chinese pharmaceutical company Tonghua Dongbao Pharmaceutical Co., Ltd. have further intensified t…
Ypsomed is adding to existing infrastructure at the Solothurn facility and creating around 100 new jobs over the coming…
The Ypsomed Group will also be securing its position as a technology leader in the field of injection and infusion syste…